hpg1860
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2019 (NCT04480697)
Timeline
Indications
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05338034 | Phase 2 | Nov 22, 2021 | Arizona Liver Health, Hepagene (Shanghai) Co., Ltd. |
| NCT04480697 | Phase 1 | Oct 10, 2019 | Hepagene (Shanghai) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hepagene (Shanghai) Co., Ltd. | For profit | 2 | 2 | 2 | 2019 |
| Arizona Liver Health | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1